Delcath Systems, Inc. (DCTH)
| Market Cap | 363.50M |
| Revenue (ttm) | 85.23M |
| Net Income (ttm) | 2.70M |
| Shares Out | 34.45M |
| EPS (ttm) | 0.07 |
| PE Ratio | 150.71 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,930 |
| Open | 10.75 |
| Previous Close | 10.84 |
| Day's Range | 10.53 - 10.87 |
| 52-Week Range | 8.12 - 18.23 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+108.63%) |
| Earnings Date | May 7, 2026 |
About DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 108.63% from the latest price.
News
Delcath Systems to Host First Quarter 2026 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® H...
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Soc...
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Earnings Call Transcript: Q4 2025
Record 2025 revenue of $85.2M driven by >40% volume growth and expanding treatment centers, with 2026 guidance of at least $100M revenue and strong gross margins. CHOPIN trial data publication and commercial expansion are expected to further accelerate growth.
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today a...
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...
Delcath Systems Earnings Call Transcript: Q3 2025
Q3 2025 featured strong revenue growth, positive Chopin trial results, and expanded site activations, though average revenue per kit declined due to NDRA pricing. Guidance reflects seasonality and clinical trial competition, with robust cash reserves supporting ongoing R&D and expansion.
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...
Delcath Systems to Host Third Quarter 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...
Delcath Systems Transcript: Study Result
The CHOPIN phase II trial showed that combining PHP with ipilimumab and nivolumab significantly improved progression-free and overall survival in metastatic uveal melanoma, with manageable toxicity. Experts consider the results practice-changing and anticipate broader adoption and protocol expansion, especially in the U.S.
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary...
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the result...
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the accept...
Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference
HEPZATO KIT's commercial rollout is driving revenue growth, with 22 active centers and plans to reach 40 next year. Expansion into new cancer indications and compliance with NDRA are shaping financial and operational strategies, while ongoing trials aim to broaden clinical adoption.
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the f...